Lookup NU author(s): Professor Caroline Austin
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
Because of their essentiality for DNA replication, transcription, and repair, type II topoisomerases are targets for antibacterial and anticancer drugs. There are two type II topoisomerases in humans, topoisomerase II alpha (TOP2A) and topoisomerase II beta (TOP2B), and two in bacteria, gyrase and topoisomerase IV. Inhibition of one or both of the human type II topoisomerases by antibacterial compounds targeting their bacterial counterparts could result in toxicity. In addition, side effects of anticancer drugs targeting TOP2A could result from inhibition of TOP2B. A simple and rapid biochemical assay for the activity of TOP2A and TOP2B would be advantageous for screening for novel inhibitors, testing them for selectivity for one enzyme over the other, and testing for potential toxicity of antibacterial type II topoisomerases mediated by human topoisomerase II inhibition. In this paper, we show that a previously reported high-throughput, fluorescence anisotropy-based assay for ATP-dependent relaxation of supercoiled DNA by human TOP2A can also be used under identical conditions for human TOP2B. We used this assay to compare the potencies versus both enzymes of 19 compounds reported in the literature to inhibit human and/or bacterial type II topoisomerases. We also used the assay to investigate the effect of ATP concentration on inhibitor potencies. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
Author(s): Shapiro AB, Austin CA
Publication type: Article
Publication status: Published
Journal: Analytical Biochemistry
Print publication date: 01/03/2014
Online publication date: 03/12/2013
Acceptance date: 24/11/2013
Date deposited: 12/05/2014
ISSN (print): 0003-2697
ISSN (electronic): 1096-0309
Publisher: Elsevier Inc.
Altmetrics provided by Altmetric